3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Congenital Abnormalities
2
Wilms Tumor
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Neutropenia
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Neutrophilic, Chronic
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Rituximab
134
Cyclophosphamide
126
Peripheral Blood Stem Cell Transplantation
74
fludarabine phosphate
71
Filgrastim
62
Etoposide
56
Bortezomib
44
Vincristine
43
Mycophenolic Acid
43
Whole-Body Irradiation
42
Cytarabine
42
Cyclosporine
41
Melphalan
38
Doxorubicin
37
Radiotherapy
36
Busulfan
35
ibrutinib
34
Tacrolimus
34
Methotrexate
33
Prednisone
32
Lenalidomide
30
Bendamustine Hydrochloride
30
Antilymphocyte Serum
27
Dexamethasone
26
Carmustine
26
Granulocyte Colony-Stimulating Factor
23
ibritumomab tiuxetan
20
sargramostim
17
fludarabine
17
Methylprednisolone
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Mantle-Cell
×
Lithium Carbonate
×
Clear all
NCT00408681
2017-03-07
GVHD
Fred Hutchinson Cancer Center
Phase NA
Completed
20 enrolled
27 charts